[1] Bertuglia S, et al. Antioxidant activity of nitro derivative of aspirin against ischemia-reperfusion in hamster cheekpouch microcirculation. Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286(3):G437-43. DOI:
10.1152/ajpgi.00339.2003[2] Corazzi T, et al. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). J Pharmacol Exp Ther. 2005 Dec;315(3):1331-7. DOI:
10.1124/jpet.105.089896[3] Selvendiran K, et al. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle. 2008 Jan 1;7(1):81-8. DOI:
10.4161/cc.7.1.5103